Letrozole plus gonadotropin, and Tamoxifen plus gonadotropin, are two methods currently used worldwide in ovarian stimulation cycles for fertility preservation in patients with estrogen-receptor-positive breast cancer. Improved knowledge about the efficacy of these medications, with regard to oocyte yield, has the potential to significantly improve quality of life in reproductive-age breast cancer survivors.
Mitchell Rosen, MD
Principal Investigator
